Domestic growth, currency to propel revenues; margins ticking up sequentially - Pharmaceuticals Q2FY23 Preview
Pharmaceuticals are likely to witness a decent quarter amid strong YoY growth in domestic formulations and stable US portfolio amid favourable currency movement and some key launches. Price hikes in domestic business are expected to lead to sequential margin growth.
Growth in domestic formulations is likely to be induced by a rise in chronic and sub-chronic therapies. Cost pressure eased out in this quarter as freight cost and other lingering costs cooled off. Several new launches and ANDA approvals are expected to lead to decent topline growth.
During Q2, domestic formulations (select pack) are expected to post robust growth of 12.2% YoY to Rs 13,513 crore on the back of 1) uptick in volumes of chronic and sub-chronic therapies, 2) full quarter impact of price hikes and 3) benefits from new introductions and field force expansion. On the US front, single digit price erosion persisting in the oral solids base business is expected to be offset by 1) new launches, 2) continued momentum in specialty/complex portfolio and 3) ~7.5% YoY impetus from rupee vs. US$ movement in the last quarter. The universe (13 coverage companies) is expected to post YoY growth of ~12% to ~Rs 49,648 crore. Europe (select pack) is expected to remain muted YoY at Rs 2,817 crore as we expect a continuance of a delay in demand pick-up amid distributors and tenders’ challenges. API segment (select pack) is expected to grow ~11% YoY to Rs 4,913 crore as we expect an improvement in demand pick-up in the generics space after prolonged inventory de-stocking and delay in order amid volatility in prices. On the companies’ front, Biocon, Laurus labs and Sun Pharma are likely to see 15%+ YoY growth.
Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.